- Home
- / PHAXIAM Therapeutics
PHAXIAM Therapeutics
Stock Price
€0.5
2023-08-29
Market Capitalization
€48.7 M
2023-08-29
PHAXIAM Therapeutics Summary
Company Summary
- Overview
- PHAXIAM Therapeutics (formerly known as Erytech Pharma) is a biopharmaceutical company that develops enzyme-based medicinal products for the oncology, hematology, and immunology sectors.
- Type
- Public
- Status
- Active
- Founded
- 2004
- HQ
- Lyon, FR | view all locations
- Website
- https://phaxiam.com/en/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Martine George, Independent Director
Hilde Windels, Independent Director
Jean-Sebastien Cleiftie, Chief Business Officer
LocationsView all
3 locations detected
Lyon, Rhône-Alpes HQ
France
60 avenue Rockefeller
Cambridge, MA
United States
1 Main St #300
Princeton, NJ
United States
104 Campus Dr
PHAXIAM Therapeutics Financials
Summary Financials
- Gross profit (H1, 2024)
- €1.1M
- Net income (H1, 2024)
- (€10.6M)
- Cash (H1, 2024)
- €1.5M
- EBIT (H1, 2024)
- (€10.7M)
- Enterprise value
- $60.1M